When I was diagnosed with Parkinson’s in August 2019, a doctor told me that Sinemet (Levodopa/Carbidopa), the starter drug of ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological ... and 45,909 with Parkinson’s ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...